Six-fold in-plane magnetic anisotropy in Co-implanted ZnO (0001)

Magnetic anisotropies of Co-implanted ZnO (0001) films grown on single-crystalline Al2O3 (11 2- 0) substrates have been studied by ferromagnetic resonance (FMR) technique for different cobalt implantation doses. The FMR data show that the easy and hard axes have a periodicity of 60° in the film plane, in agreement with the hexagonal structure of the ZnO films. This six-fold in-plane magnetic anisotropy, which is observed for the first time in ZnO-based diluted magnetic semiconductors, is attributed to the substitution of cobalt on Zn sites in the ZnO structure, and a clear indication for long range ferromagnetic ordering between substitutional cobalt ions in the single-crystalline ZnO films. © 2009 American Institute of Physics

Six-fold in-plane magnetic anisotropy in Co-implanted ZnO (0001)

Magnetic anisotropies of Co-implanted ZnO (0001) films grown on single-crystalline Al2O3 (11 2- 0) substrates have been studied by ferromagnetic resonance (FMR) technique for different cobalt implantation doses. The FMR data show that the easy and hard axes have a periodicity of 60° in the film plane, in agreement with the hexagonal structure of the ZnO films. This six-fold in-plane magnetic anisotropy, which is observed for the first time in ZnO-based diluted magnetic semiconductors, is attributed to the substitution of cobalt on Zn sites in the ZnO structure, and a clear indication for long range ferromagnetic ordering between substitutional cobalt ions in the single-crystalline ZnO films. © 2009 American Institute of Physics

Six-fold in-plane magnetic anisotropy in Co-implanted ZnO (0001)

Magnetic anisotropies of Co-implanted ZnO (0001) films grown on single-crystalline Al2O3 (11 2- 0) substrates have been studied by ferromagnetic resonance (FMR) technique for different cobalt implantation doses. The FMR data show that the easy and hard axes have a periodicity of 60° in the film plane, in agreement with the hexagonal structure of the ZnO films. This six-fold in-plane magnetic anisotropy, which is observed for the first time in ZnO-based diluted magnetic semiconductors, is attributed to the substitution of cobalt on Zn sites in the ZnO structure, and a clear indication for long range ferromagnetic ordering between substitutional cobalt ions in the single-crystalline ZnO films. © 2009 American Institute of Physics

Six-fold in-plane magnetic anisotropy in Co-implanted ZnO (0001)

Magnetic anisotropies of Co-implanted ZnO (0001) films grown on single-crystalline Al2O3 (11 2- 0) substrates have been studied by ferromagnetic resonance (FMR) technique for different cobalt implantation doses. The FMR data show that the easy and hard axes have a periodicity of 60° in the film plane, in agreement with the hexagonal structure of the ZnO films. This six-fold in-plane magnetic anisotropy, which is observed for the first time in ZnO-based diluted magnetic semiconductors, is attributed to the substitution of cobalt on Zn sites in the ZnO structure, and a clear indication for long range ferromagnetic ordering between substitutional cobalt ions in the single-crystalline ZnO films. © 2009 American Institute of Physics

The ERACE‑PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem‑resistant Pseudomonas aeruginosa

The cephalosporin-β-lactamase-inhibitor-combinations, ceftolozane/tazobactam and ceftazidime/avibactam, have revolutionized treatment of carbapenem-resistant Pseudomonas aeruginosa (CR-PA). A contemporary assessment of their in vitro potency against a global CR-PA collection and an assessment of carbapenemase diversity are warranted. Isolates determined as CR-PA by the submitting site were collected from 2019-2021 (17 centers in 12 countries) during the ERACE-PA Global Surveillance Program. Broth microdilution MICs were assessed per CLSI standards for ceftolozane/tazobactam, ceftazidime/avibactam, ceftazidime, and cefepime. Phenotypic carbapenemase testing was conducted (modified carbapenem inactivation method (mCIM)). mCIM positive isolates underwent genotypic carbapenemase testing using the CarbaR, the CarbaR NxG, or whole genome sequencing. The MIC50/90 was reported as well as percent susceptible (CLSI and EUCAST interpretation). Of the 807 isolates, 265 (33%) tested carbapenemase-positive phenotypically. Of these, 228 (86%) were genotypically positive for a carbapenemase with the most common being VIM followed by GES. In the entire cohort of CR-PA, ceftolozane/tazobactam and ceftazidime/avibactam had MIC50/90 values of 2/ > 64 and 4/64 mg/L, respectively. Ceftazidime/avibactam was the most active agent with 72% susceptibility per CLSI compared with 63% for ceftolozane/tazobactam. For comparison, 46% of CR-PA were susceptible to ceftazidime and cefepime. Against carbapenemase-negative isolates, 88 and 91% of isolates were susceptible to ceftolozane/tazobactam and ceftazidime/avibactam, respectively. Ceftolozane/tazobactam and ceftazidime/avibactam remained highly active against carbapenem-resistant P. aeruginosa, particularly in the absence of carbapenemases. The contemporary ERACE-PA Global Program cohort with 33% carbapenemase positivity including diverse enzymology will be useful to assess therapeutic options in these clinically challenging organisms with limited therapies